Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer
Dylan M. Glubb(QIMR Berghofer Medical Research Institute), Federico Innocenti(AbbVie (United States)), Witold Rzyman(Gdańsk Medical University), Osman Mirza(Imperial College London), Kouros Owzar(Duke University), Eric Seiser(Children's Hospital of Philadelphia), Eloísa Jantus‐Lewintre(Hospital General Universitario De Valencia), Carlos Camps(Universitat de València), Rafał Dziadziuszko(Gdańsk Medical University), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Fred R. Hirsch(Tisch Hospital), Todd Auman(University of North Carolina at Chapel Hill), Daniel J. Crona(St. Jude Children's Research Hospital), Wei Zhang(University of Illinois Chicago), Jacek Jassem(Gdańsk Medical University), Chen Jiang, Amy S. Etheridge(University of North Carolina at Chapel Hill)
Cited by 20
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k